Masseter Treatment with Botulinum Toxin A for parafunctions and quadralized patients
Main Article Content
Abstract
INTRODUCTION
Botulinum toxin type A (BTxA) has gained worldwide popularity due to its ability to improve the lower facial contours and treat parafunctions.
MATERIALS AND METHODS
Various analyses have been conducted through Medline searches for “Botulinum”, “masseter” and “bruxism” in order to investigate the different techniques used to inject the masseter muscle with Botulinum toxin. The authors’ experiences and techniques are fully explained regarding both functional pathologies and masseter size reduction. Personal guidelines to help physicians achieve the best outcomes for each application are outlined.
Even if a definitive consensus on the use of Botulinum toxin for masseter muscle treatment cannot be reached, the authors recommend, due to their experience, three injection sites per side of the face for masseter hypertrophy and four injection sites per side for the redefinition of the inferior third of the face. Fewer units are needed to inhibit bruxism, while more units are needed in order to achieve a reduction in muscle size.
RESULTS
Results have been very good and patient satisfaction is usually very high. No side effects have been experienced as of the writing of this report.
DISCUSSION
BTxA can be used as a therapeutic agent in bruxism patients and has been widely accepted as a cosmetic agent in recent years, helping to re-establish a balance in the contours of quadralized patients due to its positive clinical outcomes. Other clinical investigations are needed to improve the long-term effectiveness of Botulinum toxin.
CONCLUSION
Botulinum toxin can be considered a safe and effective technique to treat related masseter parafunctions and to improve the shape of the lower face in quadralized patients.Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Pravnar N.: BOTOX: Broadening the Horizon of Dentistry. J Clin Diagn Res. 2014 Dec; 8(12): ZE25–ZE29
3: Redaelli A.: Botulinum Toxin A in bruxers. One year experience. Saudi Med J. 2011 Feb;32(2):156-8.
4. Wanitphakdeedecha R: The efficacy of two formulations of botulinum toxin type A for masseter reduction: a split-face comparison study. J Dermatolog Treat. 2016 Dec 6:1-4.
5. Redaelli A.: cosmetic use of BTxA in the inferior third of the face. Cosmetic Dentistry, 2, 40-47, 2008.
6. Redaelli A.: La Medicina Estetica, SEE-Editrice Firenze, May 2009 ,pp. 109-110.
7.Park YW1, Kim SG1, Jo YY2S100 and p65 expression are increased in the masseter muscle after botulinum toxin-A injection. Maxillofac Plast Reconstr Surg. 2016 Aug 26;38(1):33.).
8. Ma F, Zhai Z, Zhu S, Tang S.Ultrastructural changes in human masseter muscles after botulinum neurotoxin a injection. Muscle Nerve. 2017 Feb 10.
9. Park SY1, Park YW1, Ji YJ2, Park SW3, Kim SG4.Effects of a botulinum toxin type A injection on the masseter muscle: An animal model study. Maxillofac Plast Reconstr Surg. 2015 Feb 24;37(1):10
10. Quezada-Gaon N1, Wortsman X2, Peñaloza O3, Carrasco JE1.Comparison of clinical marking and ultrasound-guided injection of Botulinum type A toxin into the masseter muscles for treating bruxism and its cosmetic effects. J Cosmet Dermatol. 2016 Sep;15(3):238-44
11. No YA1, Ahn BH2, Kim BJ1, Kim MN1, Hong CK1.Three-dimensional CT might be a potential evaluation modality in correction of asymmetrical masseter muscle hypertrophy by botulinum toxin injection. J Cosmet Laser Ther. 2016;18(2):113-5
12. Lee HH1, Kim ST, Lee KJ, Baik HS.Effect of a second injection of botulinum toxin on lower facial contouring, as evaluated using 3-dimensional laser scanning. Dermatol Surg. 2015 Apr;41(4):439-44
13. Bhattacharjee K1, Singh M1, Bhattacharjee H1.Extended effect after a single dose of type A botulinum toxin for asymmetric masseter muscle hypertrophy. Indian J Plast Surg. 2015 May-Aug;48(2):196-9).
14. Ahn BK1, Kim YS, Kim HJ, Rho NK, Kim HS.Consensus recommendations on the aesthetic usage of botulinum toxin type A in Asians. Dermatol Surg. 2013 Dec;39(12):1843-60)
15. K lein, F. Brenner, M. S. Sato,F. Manfron Batista Ros Robert, and Karin Adriane Helme. The administration of a second BoNT-A injection is effective for better aesthetic results for the lower facial contour. An Bras Dermatol. 2014 Nov-Dec; 89(6): 878–884)
16. Aydil B1, Başaran B, Unsaler S, Süoğlu Y.The use of botulinum toxin type A in masseter muscle hypertrophy: long-term effects and lasting improvement. .Kulak Burun Bogaz Ihtis Derg. 2012 Sep-Oct;22(5):249-53
17. Bae JH1, Choi DY, Lee JG, Seo KK, Tansatit T, Kim HJ.The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy. Dermatol Surg. 2014 Dec;40(12):1334-9)
18. Klein FH1, Brenner FM2, Sato MS2, Robert FM2, Helmer KA2.Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy. An Bras Dermatol. 2014 Nov-Dec;89(6):878-84
19. Kaya B1, Apaydin N2, Loukas M3, Tubbs RS4. The topographic anatomy of the masseteric nerve: A cadaveric study with an emphasis on the effective zone of botulinum toxin A injections in masseter. J Plast Reconstr Aesthet Surg. 2014 Dec;67(12):1663-8
20. Song JH1, Cho ES1, Kim ST1, Ahn HJ2.Change of distribution and timing of bite force after botulinum toxin type A injection evaluated by a computerized occlusion analysis system. Yonsei Med J. 2014 Jul;55(4):1123-9
21. Zhang LD1, Liu Q1, Zou DR1, Yu LF2Occlusal force characteristics of masseteric muscles after intramuscular injection of botulinum toxin A(BTX - A)for treatment of temporomandibular disorder. Br J Oral Maxillofac Surg. 2016 Sep;54(7):736-40
22. Park HU1, Kim BI, Kang SM, Kim ST, Choi JH, Ahn HJChanges in masticatory function after injection of botulinum toxin type A to masticatory muscles. J Oral Rehabil. 2013 Dec;40(12):916-22).
23. Pihut M1, Ferendiuk E1, Szewczyk M1, Kasprzyk K2, Wieckiewicz M3.The efficiency of botulinum toxin type A for the treatment of masseter muscle pain in patients with temporomandibular joint dysfunction and tension-type headache. J Headache Pain. 2016;17:29
24. Sevim S1, Kaleağası H2, Fidancı H2.Sleep bruxism possibly triggered by multiple sclerosis attacks and treated successfully with botulinum toxin: Report of three cases. Mult Scler Relat Disord. 2015 Sep;4(5):403-5) .
25. Wei J1, Xu H, Dong J, Li Q, Dai C.Prolonging the duration of masseter muscle reduction by adjusting the masticatory movements after the treatment of masseter muscle hypertrophy with botulinum toxin type a injection. Dermatol Surg. 2015 Jan;41 Suppl 1:S101-9